Scarica l'app Stockscreener
9.69
2.76%
0.26
Precedente Chiudi:
$9.43
Aprire:
$9.37
Volume 24 ore:
35,844
Relative Volume:
0.36
Capitalizzazione di mercato:
$159.93M
Reddito:
$54,000
Utile/perdita netta:
$-210.26M
Rapporto P/E:
-12.27
EPS:
-0.79
Flusso di cassa netto:
$-159.01M
1 W Prestazione:
+6.25%
1M Prestazione:
+21.28%
6M Prestazione:
-30.58%
1 anno Prestazione:
-67.91%
Intervallo 1D:
$9.37
$9.81
Intervallo di 1 settimana:
$8.46
$9.84
Portata 52W:
$7.65
$38.40
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Nome
Lyell Immunopharma Inc
Settore
Industria
Telefono
650 695-0677
Indirizzo
201 HASKINS WAY, SOUTH SAN FRANCISCO
Confronta LYEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
9.69 | 159.93M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-30 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-06-27 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | BofA Securities | Buy |
| 2021-07-12 | Iniziato | Goldman | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Overweight |
| 2021-07-12 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie
Lyell’s lymphoma therapy shows high response rate in trial - Investing.com
Lyell’s lymphoma therapy shows high response rate in trial By Investing.com - Investing.com Nigeria
Lyell Immunopharma Announces Promising CAR T-Cell Trial Data - TipRanks
Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial - marketscreener.com
Lyell Immunopharma (LYEL) Releases Promising Results from LYL314 Trial | LYEL Stock News - GuruFocus
Lyell Immunopharma Announces Positive Clinical Data From Phase 1/2 Trial Of Lyl314 For The Treatment Of Aggressive Large B-Cell Lymphoma - MarketScreener
Lyell Immunopharma Announces Positive New Clinical Data - GlobeNewswire
Lyell Immunopharma (LYEL) Strengthens Leadership Team with Key A - GuruFocus
Lyell Immunopharma (LYEL) Announces Key Executive Appointments | LYEL Stock News - GuruFocus
Lyell Immunopharma Expands Board, Appoints New Director - TipRanks
Lyell Immunopharma Strengthens Clinical And Commercial Capabilities With Key Board And Executive Appointments - marketscreener.com
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire
Lyell Immunopharma Strengthens Leadership: Key Hires from BMS, Amgen Shape CAR T-cell Future - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Raised to Hold at Wall Street Zen - Defense World
From Collapse to Comeback: Lyell Immunopharma’s Stock Surge Signals Turning Point - FXLeaders
From Collapse to Comeback: Lyell Immunopharma's Stock Surge Signals Turning Point—Cancer Breakthrough? - FXLeaders
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewswire
Lyell Immunopharma Showcases Next-Gen Cancer Therapies at Major Goldman Sachs Healthcare Event - Stock Titan
Imugene CMO and CEO talk trial momentum and immuno-oncology progress - Proactive Investors
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Lyell Immunopharma (LYEL) Trading Resumes with Renewed Focus | L - GuruFocus
Lyell Immunopharma (LYEL) Faces Trading Halt Due to Volatility | - GuruFocus
Lyell Immunopharma (LYEL) Faces Trading Halt Due to Volatility | LYEL Stock News - GuruFocus
Morgan Stanley, Walmart, Pfizer and more: Full list of over 150 American companies laying off employees in June - The Economic Times
Samsung may incorporate Perplexity's AI tech in its phones - Yahoo News
UK Government announced funding for NHS hospital maintenance - Yahoo
Electricity prices rise in the summer. What can you do? - Yahoo
Dai-ichi Life to acquire 15% stake in British insurer M&G - Yahoo
Should You Buy AGNC Investment While It's Below $10? - Yahoo
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? - Yahoo
Diakonos Oncology secures $20m for Phase II trial of glioblastoma treatment - Yahoo
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Position in Enhabit, Inc. (NYSE:EHAB) - Defense World
Deutsche Bank AG Grows Stock Holdings in LCNB Corp. (NASDAQ:LCNB) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Deutsche Bank AG Invests $244,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Markel Group Inc. (NYSE:MKL) Stake Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 36,555 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $146,000 Stake in Grab Holdings Limited (NASDAQ:GRAB) - Defense World
Tiptree Inc. (NASDAQ:TIPT) Shares Sold by Millennium Management LLC - Defense World
Cetera Investment Advisers Grows Stock Holdings in Immersion Co. (NASDAQ:IMMR) - Defense World
Mondelez sues Aldi over packaging similarities - Yahoo
Report: Airbnb brought $900M to Louisiana in 2024 - Yahoo News
BNP Paribas Financial Markets Takes $162,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma (NASDAQ:LYEL) vs. Astellas Pharma (OTCMKTS:ALPMY) Critical Review - Defense World
Lyell Immunopharma (LYEL) Trading Pause Ahead of Important Annou - GuruFocus
Northern Trust Corp Sells 45,853 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Imugene appoints Dr John Byon as chief medical officer to lead next phase of clinical development - Proactive Investors
Lyell Immunopharma Announces 1-for-20 Reverse Stock Split - TipRanks
D. E. Shaw & Co. Inc. Boosts Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma Stockholders Approve Key Proposals - TipRanks
Lyell Immunopharma: Q1 Earnings Snapshot - The Washington Post
Lyell Immunopharma Inc Azioni (LYEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lyell Immunopharma Inc Azioni (LYEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ramachandra Sumant | Director |
Mar 21 '25 |
Buy |
0.58 |
200,000 |
115,220 |
200,000 |
| Klausner Richard | Director |
Mar 14 '25 |
Buy |
0.60 |
158,000 |
94,942 |
843,365 |
| Newton Charles W. | Chief Financial Officer |
Mar 17 '25 |
Buy |
0.56 |
200,000 |
111,620 |
200,000 |
| Seely Lynn | President and CEO |
Mar 14 '25 |
Buy |
0.61 |
175,000 |
106,190 |
712,500 |
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):